Cargando…
Continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications
BACKGROUND/OBJECTIVE: We retrospectively analyzed the effective and safety of continuous low-dose cyclophosphamide combined with prednisone (CP) in relapsed and refractory multiple myeloma (RRMM) patients with severe complications. METHODS: A total of 130 RRMM patients with severe complications were...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240086/ https://www.ncbi.nlm.nih.gov/pubmed/37284198 http://dx.doi.org/10.3389/fonc.2023.1185991 |
_version_ | 1785053667156557824 |
---|---|
author | Shi, Haotian Wei, Wei Peng, Rong Chen, Haimin Zhou, Nian Wu, Lixia Yu, Wenjun Zhao, Wenhao Hou, Jian Zhou, Fan |
author_facet | Shi, Haotian Wei, Wei Peng, Rong Chen, Haimin Zhou, Nian Wu, Lixia Yu, Wenjun Zhao, Wenhao Hou, Jian Zhou, Fan |
author_sort | Shi, Haotian |
collection | PubMed |
description | BACKGROUND/OBJECTIVE: We retrospectively analyzed the effective and safety of continuous low-dose cyclophosphamide combined with prednisone (CP) in relapsed and refractory multiple myeloma (RRMM) patients with severe complications. METHODS: A total of 130 RRMM patients with severe complications were enrolled in this study, among which 41 patients were further given bortezomib, lenalidomide, thalidomide or ixazomib on the basis of CP regimen (CP+X group). The response to therapy, adverse events (AEs), overall survival (OS) and progression-free survival (PFS) were recorded. RESULTS: Among the 130 patients, 128 patients received therapeutic response assessment, with a complete remission rate (CRR) and objective response rate (ORR) of 4.7% and 58.6%, respectively. The median OS and PFS time were (38.0 ± 3.6) and (22.9±5.2) months, respectively. The most common AEs were hyperglycemia (7.7%), pneumonia (6.2%) and Cushing’s syndrome (5.4%). In addition, we found the pro-BNP/BNP level was obviously decreased while the LVEF (left ventricular ejection fraction) was increased in RRMM patients following CP treatment as compared with those before treatment. Furthermore, CP+X regimen further improved the CRR compared with that before receiving the CP+X regimen (24.4% vs. 2.4%, P=0.007). Also, both the OS and PFS rates were significantly elevated in patients received CP+X regimen following CP regimen as compared with the patients received CP regimen only. CONCLUSION: This study demonstrates the metronomic chemotherapy regimen of CP is effective to RRMM patients with severe complications. |
format | Online Article Text |
id | pubmed-10240086 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102400862023-06-06 Continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications Shi, Haotian Wei, Wei Peng, Rong Chen, Haimin Zhou, Nian Wu, Lixia Yu, Wenjun Zhao, Wenhao Hou, Jian Zhou, Fan Front Oncol Oncology BACKGROUND/OBJECTIVE: We retrospectively analyzed the effective and safety of continuous low-dose cyclophosphamide combined with prednisone (CP) in relapsed and refractory multiple myeloma (RRMM) patients with severe complications. METHODS: A total of 130 RRMM patients with severe complications were enrolled in this study, among which 41 patients were further given bortezomib, lenalidomide, thalidomide or ixazomib on the basis of CP regimen (CP+X group). The response to therapy, adverse events (AEs), overall survival (OS) and progression-free survival (PFS) were recorded. RESULTS: Among the 130 patients, 128 patients received therapeutic response assessment, with a complete remission rate (CRR) and objective response rate (ORR) of 4.7% and 58.6%, respectively. The median OS and PFS time were (38.0 ± 3.6) and (22.9±5.2) months, respectively. The most common AEs were hyperglycemia (7.7%), pneumonia (6.2%) and Cushing’s syndrome (5.4%). In addition, we found the pro-BNP/BNP level was obviously decreased while the LVEF (left ventricular ejection fraction) was increased in RRMM patients following CP treatment as compared with those before treatment. Furthermore, CP+X regimen further improved the CRR compared with that before receiving the CP+X regimen (24.4% vs. 2.4%, P=0.007). Also, both the OS and PFS rates were significantly elevated in patients received CP+X regimen following CP regimen as compared with the patients received CP regimen only. CONCLUSION: This study demonstrates the metronomic chemotherapy regimen of CP is effective to RRMM patients with severe complications. Frontiers Media S.A. 2023-05-22 /pmc/articles/PMC10240086/ /pubmed/37284198 http://dx.doi.org/10.3389/fonc.2023.1185991 Text en Copyright © 2023 Shi, Wei, Peng, Chen, Zhou, Wu, Yu, Zhao, Hou and Zhou https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Shi, Haotian Wei, Wei Peng, Rong Chen, Haimin Zhou, Nian Wu, Lixia Yu, Wenjun Zhao, Wenhao Hou, Jian Zhou, Fan Continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications |
title | Continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications |
title_full | Continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications |
title_fullStr | Continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications |
title_full_unstemmed | Continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications |
title_short | Continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications |
title_sort | continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240086/ https://www.ncbi.nlm.nih.gov/pubmed/37284198 http://dx.doi.org/10.3389/fonc.2023.1185991 |
work_keys_str_mv | AT shihaotian continuouslowdosecyclophosphamideplusprednisoneinthetreatmentofrelapsedandrefractorymultiplemyelomawithseverecomplications AT weiwei continuouslowdosecyclophosphamideplusprednisoneinthetreatmentofrelapsedandrefractorymultiplemyelomawithseverecomplications AT pengrong continuouslowdosecyclophosphamideplusprednisoneinthetreatmentofrelapsedandrefractorymultiplemyelomawithseverecomplications AT chenhaimin continuouslowdosecyclophosphamideplusprednisoneinthetreatmentofrelapsedandrefractorymultiplemyelomawithseverecomplications AT zhounian continuouslowdosecyclophosphamideplusprednisoneinthetreatmentofrelapsedandrefractorymultiplemyelomawithseverecomplications AT wulixia continuouslowdosecyclophosphamideplusprednisoneinthetreatmentofrelapsedandrefractorymultiplemyelomawithseverecomplications AT yuwenjun continuouslowdosecyclophosphamideplusprednisoneinthetreatmentofrelapsedandrefractorymultiplemyelomawithseverecomplications AT zhaowenhao continuouslowdosecyclophosphamideplusprednisoneinthetreatmentofrelapsedandrefractorymultiplemyelomawithseverecomplications AT houjian continuouslowdosecyclophosphamideplusprednisoneinthetreatmentofrelapsedandrefractorymultiplemyelomawithseverecomplications AT zhoufan continuouslowdosecyclophosphamideplusprednisoneinthetreatmentofrelapsedandrefractorymultiplemyelomawithseverecomplications |